
LLY
股票Eli Lilly and Co
- 总部
- US
- 行业
- 制药
- 发行时间
- 1985-01-13
- 流通股
- 942M
区间表现
4 天前关键指标
4 天前- 市值
- $1.06T
- 企业价值
- $1.10T
- 市盈率 (TTM)
- 41.85
- 预期市盈率
- 24.92
- 市盈率 (年)
- 51.25
- PEG
- 1.29
- 市净率
- 38.29
- 市销率 (TTM)
- 14.64
- 市销率 (年)
- 16.23
- EV / EBITDA
- 32.65×
- EV / 营收
- 15.17×
- 每股收益 (TTM)
- $28.15
- 每股收益 (年)
- $22.95
- 基本每股收益 (TTM)
- $28.15
- 每股净资产
- $28.09
- 毛利率
- 82.83%
- 营业利润率
- 43.63%
- 净利率
- 34.99%
- 净资产收益率 (ROE)
- 101.31%
- 总资产收益率 (ROA)
- 22.73%
- 投资回报率 (ROI)
- 37.71%
- 每股 EBITDA
- $37.37
- 每股营收 (TTM)
- $80.64
- 营收增长 (TTM YoY)
- +47.44%
- 营收增长 (季 YoY)
- +55.55%
- EPS 增长 (TTM YoY)
- +128.83%
- 股息率 (预期)
- 0.61%
- 股息率 (TTM)
- 0.53%
- 每股股息 (TTM)
- $5.91
- 派息率
- 22.10%
- 流动比率
- 1.58
- 速动比率
- 0.78
- 负债权益比
- 1.60
- 长期负债权益比
- 1.54
- Beta
- 0.53
- 波动率 (3M)
- 37.23%
分析师评级
4 天前财报
4 天前相关新闻
4 天前- Yahoo·4 天前companyEli Lilly's $1 trillion valuation cements its status as Wall Street's ultimate weight-loss play
Eli Lilly's $1 trillion comeback is powered by the company's experimental next-generation obesity drug, Reta.
- Yahoo·4 天前companyEli Lilly (LLY) Reports Positive Phase 1b Verve-102 Study Results
Eli Lilly and Company (NYSE:LLY) is one of the 12 Most Profitable Stocks to Invest In. On May 25, 2026, Eli Lilly and Company (NYSE:LLY) announced positive Phase 1b Heart-2 study results for Verve-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood […]
- Yahoo·4 天前companyWhy Eli Lilly (LLY) Stock Is Trading Up Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the afternoon session after CVS restored Zepbound as a co-preferred option and simultaneously added Lilly's new oral obesity pill Foundayo, making Eli Lilly's full obesity medication portfolio accessible to all three of America's largest pharmacy benefit managers for the first time.
- Yahoo·5 天前companyEli Lilly Jumps as CVS Expands Weight-Loss Drug Coverage
The change could improve patient access and support future sales growth.
- Yahoo·5 天前companyCVS Restores Coverage for Lilly's Zepbound
The move gives patients broader access to Lilly's obesity drugs and strengthens competition with Novo Nordisk.
- Yahoo·5 天前companyLilly Presses Ahead As $529 Billion Drug Pricing Fight Looms
Lilly will continue global launches despite MFN pricing uncertainty, Japan price cuts, and rising obesity-drug competition.
- Yahoo·5 天前company2 Mega-Cap Stocks on Our Buy List and 1 We Find Risky
Megacap stocks dominate their sectors and their actions influence economies worldwide. The flip side though is that their sheer size means they have less room for explosive growth as scale works against them.
- Yahoo·5 天前companyEli Lilly Expands Vaccine Push with Three Acquisitions, Reuters Reports
Eli Lilly and Company (NYSE:LLY) is included among the 10 Best Reddit Stocks to Buy According to Billionaires. On May 26, Reuters reported that Eli Lilly and Company (NYSE:LLY) plans to acquire three vaccine developers in deals worth up to $3.8 billion combined, marking a deeper push into infectious disease prevention. The US drugmaker said […]
